Clinical trial
VNP20009 in Treating Patients With Advanced or Metastatic Solid Tumors That Have…
NCT00004216 · Vion Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00004216 |
|---|---|
| Title | VNP20009 in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Previous Therapy |
| Official title | A Phase I Trial of a Live, Genetically Modified Salmonella Typhimurium (VNP20009) for the Treatment of Cancer by Intratumoral Injection |
| Lead sponsor | Vion Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Biological, Drug |
| Interventions | salmonella VNP20009, cefixime, ceftriaxone sodium, ciprofloxacin, trimethoprim-sulfamethoxazole |
| Start date | Aug 1, 1999 |
| Completion | Jan 1, 2008 |
| First posted | Feb 25, 2004 |
| Last update posted | Jul 18, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: